Original researchThe European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna
Under a Creative Commons license
open access
ESMO-MCBS
quality control
clinical benefit
metastatic disease
Cited by (0)
Competing interests: GP has received honoraria for lectures by Merck Serono, Amgen, Bayer, Servier, Lilly, Celgene, Roche and Sanofi Aventis. RP has received honoraria for lectures or advisory boards by AstraZeneca, Böhringer Ingelheim, Lilly, MSD, Pfizer, Roche and Synta. MP has received research support by Böhringer Ingelheim, GSK, MSD, Roche and honoraria by BMS, Novartis, CMC Contrast, GSK, Mundipharma and Roche. MS has received honoraria for lectures by Pfizer, BMS, Novartis, Roche and Astellas. CCZ has received honoraria for advisory boards by Bristol Myers-Squibb, AstraZeneca, Imugene and Roche. All remaining authors have declared no conflict of interest.
Provenance and peer review: Commissioned; internally peer reviewed.
© 2016 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.